US generics comprise ~30% of total revenues. So far, the company has received approval for 167 ANDAs while another 44 are pending approval, of which 22 are Para IV applications. However, Glenmark's derma portfolio is facing stiff pricing pressure in the US. Going ahead, traction from the newly commissioned US based Monroe facility will be the key determinant besides sustained product launches. We expect the US to grow at 4.5% CAGR in FY20-23E to | 3581 crore on the back of new launches....